Mental disorders and the risk of atopic dermatitis: A two-sample mendelian randomization study
Abstract
Background: Growing evidence suggests that mental disorders are associated with an increased risk of atopic dermatitis (AD). But until now, the causal association between them has been unclear. We conducted a Mendelian randomization study to determine the bidirectional causal association between atopic dermatitis and mental disorders. Simultaneously, the correlation between biomechanics and atopic dermatitis (AD) has been analyzed. Objective: This two-sample Mendelian randomization (MR) study aims to assess the causal relationship between mental disorders and the incidence of atopic dermatitis (AD). Methods: Single nucleotide polymorphisms (SNPs) associated with severe depression, generalized anxiety disorder, sleep disorders, schizophrenia, and AD were selected from the genome-wide association study (GWAS) databases. Causal effects between exposure and outcomes were analyzed using methods such as inverse-variance weighted (IVW), weighted median (WM), and MR-Egger, with results primarily assessed by the P-values, odds ratios (ORs), and 95% confidence intervals (CIs) from the IVW method. Sensitivity analyses were conducted using IVW, MR-Egger, and MR-PRESSO methods. Results: The findings indicate a positive causal effect of severe depression on the risk of developing AD, with the IVW method yielding an OR of 1.177 (95% CI 1.083–1.280, P < 0.001) and the WM method showing an OR of 1.182 (95% CI 1.061–1.317, P < 0.001). Heterogeneity tests using the IVW method’s Cochran Q test resulted in a P-value of 0.132 and an I2 of 19.34%. Pleiotropy tests with MR-PRESSO showed a P-value of 0.193, and the MR-Egger regression intercept yielded a P-value of 0.009, indicating the presence of heterogeneity or pleiotropy. No causal relationships were found between generalized anxiety disorder (OR = 1.024, 95% CI 0.996–1.052, P > 0.05), sleep disorders (OR = 0.970, 95% CI 0.928–1.014, P > 0.05), or schizophrenia (OR = 1.006, 95% CI 0.983–1.029, P > 0.05) and the incidence of AD. Conclusion: Major depressive disorder exhibits a unidirectional causal influence on Alzheimer’s disease development risk. It is recommended that patients with severe depression undergo enhanced screening and prevention for AD to mitigate the risk of developing this condition. Biomechanics plays a significant role in the onset and progression of atopic dermatitis (AD).
References
1. Steel Z, Marnane C, Iranpour C, et al. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013. International Journal of Epidemiology. 2014; 43(2): 476-493. doi: 10.1093/ije/dyu038
2. Bewley A. Commentary on Epidemiology of mental health comorbidity in patients with atopic dermatitis: An analysis of global trends from 1998 to 2022. Journal of the European Academy of Dermatology and Venereology. 2024; 38(3): 464-465. doi: 10.1111/jdv.19788
3. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. LANCET; 2020. doi: 10.1016/S0140-6736(20)31286-1
4. Bylund S, Kobyletzki L, Svalstedt M, et al. Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. Acta Dermato Venereologica. 2020; 100(12): adv00160. doi: 10.2340/00015555-3510
5. Silverberg JI, Gelfand JM, Margolis DJ, et al. Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults. British Journal of Dermatology. 2019; 181(3): 554-565. doi: 10.1111/bjd.17683
6. Sandhu JK, Wu KK, Bui TL, et al. Association Between Atopic Dermatitis and Suicidality. JAMA Dermatology. 2019; 155(2): 178. doi: 10.1001/jamadermatol.2018.4566
7. Chen C, Wang P, Zhang RD, et al. Mendelian randomization as a tool to gain insights into the mosaic causes of autoimmune diseases. Autoimmunity reviews; 2022. doi: 10.1016/j.autrev.2022.103210
8. Chang L, Zhou G, Xia J. mGWAS-Explorer 2.0: Causal Analysis and Interpretation of Metabolite—Phenotype Associations. Metabolites. 2023; 13(7): 826. doi: 10.3390/metabo13070826
9. Manousaki D, Mitchell R, Dudding T, et al. Genome-wide Association Study for Vitamin D Levels Reveals 69 Independent Loci. The American Journal of Human Genetics. 2020; 106(3): 327-337. doi: 10.1016/j.ajhg.2020.01.017
10. Mokry LE, Ross S, Ahmad OS, et al. Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study. PLOS Medicine. 2015; 12(8): e1001866. doi: 10.1371/journal.pmed.1001866
11. Burgess S, Scott RA, Timpson NJ, et al. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. European Journal of Epidemiology. 2015; 30(7): 543-552. doi: 10.1007/s10654-015-0011-z
12. Bowden J, Davey Smith G, Haycock PC, et al. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genetic Epidemiology. 2016; 40(4): 304-314. doi: 10.1002/gepi.21965
13. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. European Journal of Epidemiology. 2017; 32(5): 377-389. doi: 10.1007/s10654-017-0255-x
14. Bowden J, Spiller W, Del Greco M F, et al. Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression. International Journal of Epidemiology. 2018; 47(6): 2100-2100. doi: 10.1093/ije/dyy265
15. Burgess S, Butterworth A, Thompson SG. Mendelian Randomization Analysis with Multiple Genetic Variants Using Summarized Data. Genetic Epidemiology. 2013; 37(7): 658-665. doi: 10.1002/gepi.21758
16. Zhang J. Mendelian Randomization Study Implies Causal Linkage Between Telomere Length and Juvenile Idiopathic Arthritis in a European Population. Journal of Inflammation Research. 2022; Volume 15: 977-986. doi: 10.2147/jir.s354619
17. Lawlor DA, Harbord RM, Sterne JAC, et al. Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. Statistics in Medicine. 2008; 27(8): 1133-1163. doi: 10.1002/sim.3034
18. Yang T, Huang X, Xu J, et al. Explore the Underlying Mechanism Between Atopic Dermatitis and Major Depressive Disorder. Frontiers in Genetics. 2021; 12. doi: 10.3389/fgene.2021.640951
19. Zhang J, Loman L, Oldhoff JM, et al. Beyond Anxiety and Depression: Loneliness and Psychiatric Disorders in Adults with Atopic Dermatitis. Acta Dermato-Venereologica. 2023; 103: adv9378. doi: 10.2340/actadv.v103.9378
20. Pondeljak N, Lugović-Mihić L. Stress-induced Interaction of Skin Immune Cells, Hormones, and Neurotransmitters. Clinical Therapeutics. 2020; 42(5): 757-770. doi: 10.1016/j.clinthera.2020.03.008
21. Hoshino Y, Kirima K, Arichika N, et al. Long-term application of MC903 in mice prolongs the characteristic symptoms of atopic dermatitis, such as inflammation, skin barrier dysfunction, and itching. Experimental Animals; 2024. doi: 10.1538/expanim.24-0088
22. Biazus Soares G, Hashimoto T, Yosipovitch G. Atopic Dermatitis Itch: Scratching for an Explanation. Journal of Investigative Dermatology. 2024; 144(5): 978-988. doi: 10.1016/j.jid.2023.10.048
23. Fujii K, Miyagawa R, Tanaka R, et al. MrgprA3+ Primary Sensory Neurons Mediate Acute Allergic Itch Responses in Atopic Dermatitis Model Mice. Biological and Pharmaceutical Bulletin. 2024; 47(10): 1624-1630. doi: 10.1248/bpb.b24-00522
24. Prakoeswa CRS, Damayanti, Anggraeni S, et al. The Role of Moisturizer Containing Anti‐inflammatory on Skin Hydration in Mild‐Moderate Atopic Dermatitis Patients. Dermatology Research and Practice. 2024; 2024(1). doi: 10.1155/drp/3586393
25. Weber I, Woolhiser E, Keime N, et al. Clinical Efficacy of Nutritional Supplements in Atopic Dermatitis: Systematic Review. JMIR Dermatology. 2023; 6: e40857. doi: 10.2196/40857
26. Yosipovitch G, Canchy L, Ferreira BR, et al. Integrative Treatment Approaches with Mind–Body Therapies in the Management of Atopic Dermatitis. Journal of Clinical Medicine. 2024; 13(18): 5368. doi: 10.3390/jcm13185368
27. Jia Y, Hu J, An K, et al. Hydrogel dressing integrating FAK inhibition and ROS scavenging for mechano-chemical treatment of atopic dermatitis. Nature Communications. 2023; 14(1). doi: 10.1038/s41467-023-38209-x
28. Liang Q, Xiang H, Xin M, et al. A wearable iontophoresis enables dual-responsive transdermal delivery for atopic dermatitis treatment. Journal of Colloid and Interface Science. 2025; 678: 908-919. doi: 10.1016/j.jcis.2024.08.209
29. Binder C, Sellberg F, Cvetkovski F, et al. Siplizumab, an Anti-CD2 Monoclonal Antibody, induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin In Vitro. Frontiers in Immunology. 2020; 11. doi: 10.3389/fimmu.2020.592553
30. Cvetkovski F, Razavi R, Sellberg F, et al. Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro. American Journal of Transplantation. 2023; 23(10): 1603-1611. doi: 10.1016/j.ajt.2023.05.032
Copyright (c) 2025 Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright on all articles published in this journal is retained by the author(s), while the author(s) grant the publisher as the original publisher to publish the article.
Articles published in this journal are licensed under a Creative Commons Attribution 4.0 International, which means they can be shared, adapted and distributed provided that the original published version is cited.
Submit a Paper
